Full Breakdown
Indian Equity Markets Decline Following U.S. Tariff Announcement
9/27/2025, 11:44:11 PM
Impact of U.S. Tariffs on Indian Pharmaceuticals
On September 26, 2025, Indian pharmaceutical stocks experienced a notable decline, falling by 2.6% after U.S. President Donald Trump announced a 100% tariff on branded and patented drugs, effective October 1. This decision impacted all 20 constituents of the Nifty Pharma index, with heavyweight Sun Pharmaceutical Industries dropping by 3.4%. The U.S. accounts for over a third of India's drug exports, primarily consisting of generics, which saw a 20% increase to approximately $10.5 billion in fiscal 2025. Analysts, including Pankaj Pandey from ICICI Securities, indicated that while the immediate impact of the tariffs may be limited due to India's focus on generics, uncertainty remains regarding the future inclusion of complex generics and biosimilars under the tariff regime.
Broader Market Reactions
The announcement of the tariffs contributed to a broader decline in Indian equity markets on the same day. The Nifty 50 index fell by 236.15 points, or 0.95%, while the Sensex dropped by 733.22 points, or 0.90%. The market's response was characterized by widespread selling, with only six of the 50 stocks in the Nifty 50 ending the day in positive territory. The Nifty Mid-small IT & Telecom index was particularly hard-hit, declining by 3.33%. Overall, the market breadth was extremely negative, with 2,423 stocks declining compared to just 627 that gained.
Criticism and Concerns
Critics of the tariff announcement argue that the sudden imposition of such tariffs could destabilize the Indian pharmaceutical sector, which relies heavily on exports to the U.S. The uncertainty surrounding future tariffs on complex generics and biosimilars has raised concerns among industry stakeholders about long-term growth prospects. Additionally, analysts from Jefferies and Goldman Sachs noted that the discretionary demand for Indian IT service providers remains unchanged, posing risks to revenue growth expectations for FY27.
Official Statements & Responses
In response to the market's reaction, analysts emphasized the need for clarity regarding the scope of the tariffs. Pankaj Pandey stated, "That being said, uncertainty still remains whether complex generics and biosimilars will come under tariff embargo in the future." This sentiment reflects the broader apprehension within the industry regarding the potential long-term implications of the U.S. tariff policy.
Verbatim Quotes
- “The news came that US has imposed 100% import tariff on branded and patented pharmaceutical products.” — President Donald Trump
- “demand recovery is patchy as of now” — Analysts at Macquarie
- “All the broad & sectoral indices ended the day in red The extent of the market decline today is reflected in all the broad market indices ending the day in red.” — NSE Report
What's Next
As the market adjusts to the new tariff landscape, stakeholders in the Indian pharmaceutical and IT sectors are closely monitoring developments. Future announcements regarding tariff policies and their implications for trade will be critical in shaping market sentiment and investment strategies in the coming months.
